Research

This journal examines the clinical course of autoimmune hepatitis (AIH) in Hispanic and African American patients at a South Bronx hospital. The findings contribute to a better understanding of AIH in diverse racial and ethnic groups, emphasizing the need for tailored healthcare strategies.

This journal compares the effectiveness of Heplisav-B and standard hepatitis B vaccines as boosters for healthcare workers with low immunity to hepatitis B, measured by anti-HBs antibody levels. Results show that Heplisav-B offers a significantly higher seropositivity rate (99.4%) compared to the standard vaccine (92.7%).

This journal outlines best practices for engaging communities affected by chronic hepatitis B, emphasizing the importance of involving individuals with lived experiences in public health initiatives to improve diagnosis and treatment outcomes.

This report outlines progress toward eliminating mother-to-child transmission of hepatitis B virus (HBV) in the Americas from 2012 to 2022. It highlights improvements in vaccination coverage, including birth doses, but also notes coverage declines in some countries, which could hinder elimination goals. The report emphasizes the need for maintaining high vaccination rates, expanding hepatitis B testing for pregnant women, and ensuring timely treatment for newborns.

This article highlights groundbreaking research on tuberculosis (TB) treatment, revealing why a key TB drug remains effective against resistant strains. Rutgers Health researchers uncover the molecular mechanisms that enable this drug to combat TB bacteria, potentially inspiring improved treatments and drug development strategies. The findings emphasize the need for continued research to address antibiotic resistance and enhance global TB control efforts.

This journal explores the evolution of HIV diagnostic testing, from early antibody-based methods to advanced molecular and rapid point-of-care technologies. It highlights the impact of these innovations on early detection, treatment initiation, and global efforts to control HIV transmission.

The National Health and Nutrition Examination Survey (NHANES) underestimates the true prevalence of hepatitis C virus (HCV) infection in the U.S. due to inadequate representation of certain populations. Two models were developed to provide more accurate estimates of HCV prevalence among U.S. adults from 2017 to 2020.

This webinar recording features updates on new hepatitis C prevalence estimates.

Tens of thousands of new cases of viral hepatitis occur every year in the United States. Viral hepatitis is a serious public health threat that kills thousands of Americans annually and is a leading cause of liver cancer. Hepatitis A and hepatitis B are vaccine-preventable and hepatitis C can be cured. The Viral Hepatitis Surveillance Report — United States, 2022 presents information from the ongoing, systematic collection, analysis, and interpretation of viral hepatitis-related data.

AHEAD is "one tool" supporting and/or tracking the Ending the HIV Epidemic in the U.S. (EHE). AHEAD helps track the six EHE indicators in areas with the highest burden of HIV. It complements and serves as one of many important implementation elements of the EHE initiative and the National HIV/AIDS Strategy. This interactive dashboard can be used to inform planning and is a starting place to explore other HIV data sources.